Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Michigan: - Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- C S Mott Children's Hospital — Ann Arbor, Michigan
- Bronson Battle Creek — Battle Creek, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in Michigan: - Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital — Chelsea, Michigan
- University of Michigan Health - Sparrow Lansing — Lansing, Michigan
- Trinity Health Saint Mary Mercy Livonia Hospital — Livonia, Michigan
Phase 3 Recruiting Industry
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …
Sponsor: AstraZeneca
NCT ID: NCT06549595
Sites in Michigan: - Research Site — Ann Arbor, Michigan
- Research Site — Detroit, Michigan
- Research Site — Ypsilanti, Michigan
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Michigan: - Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011) — Grand Rapids, Michigan
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Michigan: - University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- Battle Creek Health Systm — Battle Creek, Michigan
- Karmanos Cancer Institute - Wayne State University — Detroit, Michigan
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Sites in Michigan: - University of Michigan Health System — Ann Arbor, Michigan
Phase 3 Recruiting Industry
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be m…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06091254
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
- Bronson Battle Creek — Battle Creek, Michigan
- Corewell Health Dearborn Hospital — Dearborn, Michigan
- Children's Hospital of Michigan — Detroit, Michigan
- Michigan State University — East Lansing, Michigan
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
- Children's Hospital of Michigan — Detroit, Michigan
- Michigan State University — East Lansing, Michigan
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan
- Bronson Methodist Hospital — Kalamazoo, Michigan
Phase 2 Recruiting Network
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that r…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05890352
Sites in Michigan: - Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health Medical Center - Brighton — Brighton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
- Trinity Health Medical Center - Canton — Canton, Michigan
Phase 2 Recruiting Academic/Other
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may st…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT04803201
Sites in Michigan: - Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
Phase 2 Recruiting Industry
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts includ…
Sponsor: Miltenyi Biomedicine GmbH
NCT ID: NCT04792489
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
Phase 2 Recruiting Industry
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibito…
Sponsor: Nurix Therapeutics, Inc.
NCT ID: NCT07221500
Sites in Michigan: - Karmanos Cancer Center — Detroit, Michigan
Phase 2 Recruiting Academic/Other
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hemato…
Sponsor: Pediatric Transplantation & Cellular Therapy Consortium
NCT ID: NCT03509961
Sites in Michigan: - Helen DeVos Children's Hospital at Spectrum Health — Grand Rapids, Michigan
Phase 1, Phase 2 Recruiting Industry
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- posi…
Sponsor: Nuvalent Inc.
NCT ID: NCT05384626
Sites in Michigan: - Henry Ford Cancer Institute — Detroit, Michigan
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Michigan: - Corewell Health ( Site 1001) — Grand Rapids, Michigan
Phase 2 Recruiting Industry
The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for st…
Sponsor: AstraZeneca
NCT ID: NCT05952024
Sites in Michigan: - Research Site — Detroit, Michigan
Phase 2 Recruiting Academic/Other
Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Days 1 and 8, cisplatin 75 mg/m2 IV on Da…
Sponsor: Dipenkumar Modi
NCT ID: NCT05852717
Sites in Michigan: - Karmanos Cancer Center (Wayne State University) — Detroit, Michigan
Phase 1 Recruiting Industry
This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
Sponsor: Ono Pharmaceutical Co., Ltd.
NCT ID: NCT05079282
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
Phase 1 Recruiting Industry
This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell N…
Sponsor: Imugene Limited
NCT ID: NCT03666000
Sites in Michigan: - Barbara Ann Karmanos Cancer Institute (Wayne State University) — Detroit, Michigan
Phase 1 Recruiting Academic/Other
A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolesce…
Sponsor: New York Medical College
NCT ID: NCT04972942
Sites in Michigan: - Helen DeVos Children's Hospital — Grand Rapids, Michigan
EARLY Phase 1 Recruiting Academic/Other
Patients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymph…
Sponsor: New York Medical College
NCT ID: NCT03719105
Sites in Michigan: - Helen De Vos — Grand Rapids, Michigan
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Michigan: - MyMichigan Medical Center Gratiot — Alma, Michigan
- MyMichigan Medical Center Alpena — Alpena, Michigan
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- Bronson Battle Creek — Battle Creek, Michigan
- OSF Saint Francis Hospital and Medical Group — Escanaba, Michigan
Recruiting Network
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
- Children's Hospital of Michigan — Detroit, Michigan
- Karmanos Cancer Institute — Detroit, Michigan
- Henry Ford Health System — Detroit, Michigan
- Helen DeVos Children's Hospital — Grand Rapids, Michigan